AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24907225 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg once daily) plus peginterferon alfa 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (total treatment duration 24 or 48 weeks based on response)
Number of subjects: 394
Study 24907225 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus peginterferon alfa 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (total treatment duration 48 weeks)
Number of subjects: 394
Study 24907225 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir group
Number of subjects: 394
Study 22996850 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of specific resistance training for the neck/shoulder muscles for 2 minutes per day 5 times a week
Number of subjects: 198
Study 22996850 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of specific resistance training for the neck/shoulder muscles for 12 minutes per day 5 times a week
Number of subjects: 198
Study 22996850 — intervention group
Group type: COMPARATOR
Intervention: Weekly information on general health (control group)
Number of subjects: 198
Study 20297703 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 6
Study 20297703 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (F‐varnish)
Number of subjects: 6
Study 17300719 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin compounds
Number of subjects: 945
Study 15604592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (0.02% for 3 min)
Number of subjects: 56
Study 15604592 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative doxorubicin (0.02% for 3 min)
Number of subjects: 56
Study 12871538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ximelagatran (24, 36, 48 or 60 mg twice daily)
Number of subjects: 350
Study 12871538 — intervention group
Group type: COMPARATOR
Intervention: Low‐molecular‐weight heparin (dalteparin) followed by warfarin
Number of subjects: 350
Study 12871538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ximelagatran
Number of subjects: 350
Study 12871538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ximelagatran and Low‐molecular‐weight heparin (dalteparin) followed by warfarin
Number of subjects: 350
Study 10357864 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% butenafine hydrochloride and 5% Melaleuca alternifolia oil in cream
Number of subjects: 60
Study 10357864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8542165 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms three times daily
Number of subjects: 30
Study 8542165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8542165 — intervention group
Group type: COMPARATOR
Intervention: Low-dose and high-dose inhaled terbutaline
Number of subjects: 30
Study 1792931 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg moclobemide
Number of subjects: 167
Study 1792931 — intervention group
Group type: COMPARATOR
Intervention: 150 mg clomipramine
Number of subjects: 167
Study 1792931 — intervention group
Group type: COMPARATOR
Intervention: 30 mg isocarboxazide
Number of subjects: 167
Study 6359972 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl combination (0.5% bupivacaine 1.06 ml per metamer + fentanyl 1.70 +/- 0.09 micrograms X kg‐1)
Number of subjects: 30
Study 6359972 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (0.5% bupivacaine 1.18 ml per metamer)
Number of subjects: 30
Study 30712198 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered complex decongestive therapy (saCDT) course
Number of subjects: 41
Study 30712198 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CTRL)
Number of subjects: 41
Study 30402575 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrotal incision hydrocelectomy
Number of subjects: 156
Study 30402575 — intervention group
Group type: COMPARATOR
Intervention: Traditional inguinal incision hydrocelectomy
Number of subjects: 156
Study 27207001 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA nerve block injection at the most common injection site with 3% mepivacaine solution
Number of subjects: 47
Study 27207001 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA nerve block injection at the anterior injection site with 3% mepivacaine solution
Number of subjects: 47
Study 27207001 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA nerve block injection at the posterior injection site with 3% mepivacaine solution
Number of subjects: 47
Study 25377582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen/thrombin‐coated collagen patch as wound dressing
Number of subjects: 27
Study 22430233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside-enhanced cardiopulmonary resuscitation
Number of subjects: 32
Study 22430233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside-enhanced cardiopulmonary resuscitation + adenosine
Number of subjects: 32
Study 22430233 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled pauses - sodium nitroprusside-enhanced cardiopulmonary resuscitation + adenosine
Number of subjects: 32
Study 22430233 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation
Number of subjects: 32
Study 20449526 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy combined with beclomethasone diproprionate through exclusively nasal inhalation (BDT group)
Number of subjects: 24
Study 20449526 — intervention group
Group type: COMPARATOR
Intervention: Only beclomethasone diproprionate through exclusively nasal inhalation (BDI group)
Number of subjects: 24
Study 17660157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/d
Number of subjects: 93
Study 17660157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 93
Study 17660157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lipid‐lowering medication)
Number of subjects: 93
Study 15642054 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) in treated patients
Number of subjects: 20
Study 15642054 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study 12145597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 155
Study 12145597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 10199766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate alone
Number of subjects: 30
Study 10199766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate with progressive resistance training (PRT)
Number of subjects: 30
Study 7755068 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg three times a day)
Number of subjects: 938
Study 7755068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 938
Study 2271752 — intervention group
Group type: EXPERIMENTAL
Intervention: URO-TS D
Number of subjects: 10
Study 2271752 — intervention group
Group type: COMPARATOR
Intervention: Bactrim F
Number of subjects: 10
Study 436200 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (100 mg) and Isosorbide Dinitrate (40 mg)
Number of subjects: 22
Study 436200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30262449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app use for managing depressive symptoms
Number of subjects: 16
Study 27023860 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 209
Study 27023860 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 209
Study 25549816 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser followed by 5FU (group III)
Number of subjects: 68
Study 25549816 — intervention group
Group type: COMPARATOR
Intervention: 5FU (group I)
Number of subjects: 68
Study 25549816 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser (group II)
Number of subjects: 68
Study 23765173 — intervention group
Group type: EXPERIMENTAL
Intervention: RTUS-guided PICC placement
Number of subjects: 48
Study 23765173 — intervention group
Group type: COMPARATOR
Intervention: Standard radiograph placement
Number of subjects: 48
Study 20509084 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 0
Study 18346063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment with 5-minute application of liposomal lidocaine cream
Number of subjects: 70
Study 18346063 — intervention group
Group type: COMPARATOR
Intervention: 30-minute application of liposomal lidocaine cream (Control)
Number of subjects: 70
Study 16010505 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac plexus block
Number of subjects: 55
Study 14667877 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ICSI with morphologically selected spermatozoa
Number of subjects: 62
Study 14667877 — intervention group
Group type: COMPARATOR
Intervention: Routine ICSI
Number of subjects: 62
Study 10809240 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin (Ico)
Number of subjects: 38
Study 10809240 — intervention group
Group type: COMPARATOR
Intervention: Glucose (Glu)
Number of subjects: 38
Study 8866584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide, 80 microg q.i.d. for 14 days
Number of subjects: 13
Study 8866584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1509526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 64
Study 1509526 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 64
Study 1509526 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 64
Study 6189335 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate (active corticosteroid preparation)
Number of subjects: 18
Study 6189335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (basal formulation only)
Number of subjects: 18
Study 31752774 — intervention group
Group type: EXPERIMENTAL
Intervention: Text 4 change SMS intervention group
Number of subjects: 1016
Study 31752774 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving group education about lifestyle modifications and written information about diet and physical activity
Number of subjects: 1016
Study 29458319 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV+
Number of subjects: 50
Study 29458319 — intervention group
Group type: COMPARATOR
Intervention: PSV
Number of subjects: 50
Study 27367818 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 21004
Study 27367818 — intervention group
Group type: COMPARATOR
Intervention: chlorthalidone
Number of subjects: 21004
Study 27367818 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 21004
Study 27367818 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin
Number of subjects: 21004
Study 24599197 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instruments
Number of subjects: 47
Study 24599197 — intervention group
Group type: COMPARATOR
Intervention: Standard instruments
Number of subjects: 47
Study 22901620 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-week dexamethasone (10 mg/m² per day on days 0-6 and 14-20)
Number of subjects: 2056
Study 22901620 — intervention group
Group type: COMPARATOR
Intervention: Continuous dexamethasone (10 mg/m² per day on days 0-20)
Number of subjects: 2056
Study 22901620 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-week dexamethasone
Number of subjects: 2056
Study 22901620 — intervention group
Group type: COMPARATOR
Intervention: Continuous dexamethasone
Number of subjects: 2056
Study 20695801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline (600 mg every 12 h)
Number of subjects: 1378
Study 20695801 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus aztreonam (1 g each every 12 h)
Number of subjects: 1378
Study 20695801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 1378
Study 20695801 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus aztreonam
Number of subjects: 1378
Study 20695801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline and Vancomycin plus aztreonam
Number of subjects: 1378
Study 18234046 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 190
Study 18234046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 15737951 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (300-480 microg subcutaneously for up to seven days)
Number of subjects: 28
Study 15737951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12506171 — intervention group
Group type: EXPERIMENTAL
Intervention: FU/LV + low‐dose bevacizumab (5 mg/kg every 2 weeks)
Number of subjects: 104
Study 12506171 — intervention group
Group type: EXPERIMENTAL
Intervention: FU/LV + high‐dose bevacizumab (10 mg/kg every 2 weeks)
Number of subjects: 104
Study 12506171 — intervention group
Group type: COMPARATOR
Intervention: FU/LV alone
Number of subjects: 104
Study 11758301 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (inspections, information distribution, sanctions)
Number of subjects: 0
Study 11758301 — intervention group
Group type: COMPARATOR
Intervention: Regular intervention (inspections, information distribution, sanctions)
Number of subjects: 0
Study 9236418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (120 i.u./kg, twice-daily subcutaneous injections)
Number of subjects: 1482
Study 9236418 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (dose-adjusted intravenous infusion)
Number of subjects: 1482
Study 9236418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (7500 i.u. once daily, subcutaneous)
Number of subjects: 1482
Study 9236418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1482
Study 8137694 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced preparation intervention (written instructions, reminder to post instructions in the bathroom, toilet seat cover with reminder, nurse-initiated telephone call)
Number of subjects: 179
Study 8137694 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation intervention (written instructions, telephone number for questions)
Number of subjects: 179
Study 3627588 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 dimethyl prostaglandin E2 (PGE2) vaginal suppository
Number of subjects: 84
Study 3627588 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm hypan plastic dilator
Number of subjects: 84
Study 3627588 — intervention group
Group type: EXPERIMENTAL
Intervention: small Laminaria japonica tent
Number of subjects: 84
Study 3627588 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study 30734090 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 15
Study 30734090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30500646 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleHealth Electronic Monitoring (THEM)
Number of subjects: 30
Study 30500646 — intervention group
Group type: COMPARATOR
Intervention: Standard Of Care (SOC)
Number of subjects: 30
Study 28600373 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiatrist-directed prehabilitation intervention including assessment and supervised exercise programme.
Number of subjects: 40
Study 28600373 — intervention group
Group type: COMPARATOR
Intervention: Control group with no prehabilitation interventions.
Number of subjects: 40
Study 28600373 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiatrist-directed prehabilitation intervention.
Number of subjects: 40
Study 25087085 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous furosemide infusion (cIV)
Number of subjects: 57
Study 25087085 — intervention group
Group type: COMPARATOR
Intervention: Bolus injections of furosemide (iIV)
Number of subjects: 57
Study 23166062 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education
Number of subjects: 100
Study 23166062 — intervention group
Group type: COMPARATOR
Intervention: Professional education (control)
Number of subjects: 100
Study 24956430 — intervention group
Group type: EXPERIMENTAL
Intervention: Roots of Empathy (ROE) program
Number of subjects: 445
Study 24956430 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention)
Number of subjects: 445
Study 19231632 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg
Number of subjects: 114
Study 19231632 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg (dose increase for patients with platelet counts <50,000 after 3 weeks)
Number of subjects: 114
Study 19231632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 19231632 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 114
Study 16707863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study 16707863 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0
Study 16707863 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding ICD to CRT
Number of subjects: 0
Study 14643092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg/day
Number of subjects: 34
Study 14643092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11103365 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewed in Turkish language
Number of subjects: 141
Study 11103365 — intervention group
Group type: COMPARATOR
Intervention: Interviewed in German language
Number of subjects: 141
Study 11103365 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish patients with good German language knowledge
Number of subjects: 141
Study 11103365 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish patients
Number of subjects: 141
Study 9059091 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms.kg‐1 fentanyl
Number of subjects: 16
Study 9059091 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms.kg‐1 fentanyl
Number of subjects: 16
Study 9059091 — intervention group
Group type: COMPARATOR
Intervention: Control (inhalational anaesthesia without fentanyl)
Number of subjects: 16
Study 8345609 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostimulating bacterial extract
Number of subjects: 166
Study 8345609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 30673055 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality evaluation using the Caliper Profile Questionnaire
Number of subjects: 40
Study 30060980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing GA (without neovascular AMD)
Number of subjects: 411
Study 30060980 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident GA
Number of subjects: 411
Study 30060980 — intervention group
Group type: EXPERIMENTAL
Intervention: GA enlargement rate in pre-existing GA
Number of subjects: 411
Study 30060980 — intervention group
Group type: EXPERIMENTAL
Intervention: GA enlargement rate in incident GA
Number of subjects: 411
Study 30060980 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group GA enlargement
Number of subjects: 411
Study 30060980 — intervention group
Group type: COMPARATOR
Intervention: AREDS2 treatment assignment
Number of subjects: 411
Study 30060980 — intervention group
Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 411
Study 30060980 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMS2 risk genotype
Number of subjects: 411
Study 30060980 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 non-risk genotype
Number of subjects: 411
Study 30060980 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE non-risk genotype
Number of subjects: 411
Study 27486544 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone (2,040 mg/d)
Number of subjects: 1462
Study 25146745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol
Number of subjects: 300
Study 25146745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 22006541 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg GS-9450
Number of subjects: 124
Study 22006541 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg GS-9450
Number of subjects: 124
Study 22006541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 22006541 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9450 treatment groups
Number of subjects: 124
Study 20209171 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC only
Number of subjects: 45
Study 20209171 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC and corresponding primer
Number of subjects: 45
Study 20209171 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC, acid etching, and Scotchbond Multipurpose
Number of subjects: 45
Study 20209171 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC and two‐step self‐etching primer
Number of subjects: 45
Study 20209171 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC and one‐step primer
Number of subjects: 45
Study 17109733 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (single-dose administration)
Number of subjects: 0
Study 15800130 — intervention group
Group type: EXPERIMENTAL
Intervention: AA plus G dialysate (Nutrineal 1.1%, 27 g of AA and Physioneal 1.36 to 3.86%)
Number of subjects: 8
Study 15800130 — intervention group
Group type: COMPARATOR
Intervention: Control dialysate (G)
Number of subjects: 8
Study 12468113 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH administered intravenously (50 microg)
Number of subjects: 20
Study 12468113 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH administered intranasally (300 microg)
Number of subjects: 20
Study 12468113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12468113 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH/vasopressin stimulation
Number of subjects: 20
Study 12468113 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (both routes)
Number of subjects: 20
Study 12468113 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. GHRH application
Number of subjects: 20
Study 12468113 — intervention group
Group type: EXPERIMENTAL
Intervention: intranasal GHRH administration
Number of subjects: 20